What to Ask Your Doctor If Your Lp(a) Is High

Disclosure: This site contains some affiliate links. We might receive a small commission at no additional cost to you.

Lipoprotein(a), written as Lp(a) and pronounced “L-P-little-a,” is a particle in the bloodstream that has emerged as one of the most important genetically determined cardiovascular risk factors. Unlike LDL cholesterol, which responds substantially to diet and medications, your Lp(a) level is largely set by your genes from early in life and changes little over time. An elevated result on a Lp(a) test does not mean a heart attack is imminent — but it does represent meaningful information worth a thorough conversation with your clinician. This article explains what Lp(a) is, what evolving guidelines say, and which questions to bring to your appointment.

What This Means in Plain Language

Lp(a) is a type of lipoprotein particle — similar in structure to LDL cholesterol — that contains an additional protein called apolipoprotein(a). This particle is thought to be pro-atherogenic (contributing to plaque buildup in arteries) and pro-thrombotic (contributing to clot formation). Research has consistently found that higher Lp(a) levels are associated with elevated risk for heart attack, stroke, and aortic valve calcification.

What makes Lp(a) unusual in cardiovascular risk assessment is how stable it is. According to updated ESC/EAS dyslipidemia guidelines highlighted by Roche Diagnostics^[1], Lp(a) levels are genetically determined, remain remarkably stable over a person’s lifetime, and are not significantly influenced by diet or exercise. This means a single test result has lasting relevance.

Levels are reported in either milligrams per deciliter (mg/dL) or nanomoles per liter (nmol/L), and the units matter because the relationship between them is not a simple fixed conversion. The National Lipid Association (NLA)^[2] classifies levels below 75 nmol/L (approximately 30 mg/dL) as low risk, 75–125 nmol/L (approximately 30–50 mg/dL) as intermediate risk, and 125 nmol/L or above (approximately 50 mg/dL or above) as high risk. When asking about your result, it helps to confirm which units were used.

Why Guidelines Pay Attention

The clinical consensus around Lp(a) has been evolving rapidly. Here is where major guideline bodies currently stand:

National Lipid Association (NLA): A 2024 focused NLA update^[2] recommended measurement of Lp(a) levels at least once in every adult for cardiovascular risk stratification. The NLA also supports cascade screening of first-degree relatives of patients with elevated Lp(a), because Lp(a) elevation runs in families.

American College of Cardiology / American Heart Association (ACC/AHA): The 2019 ACC/AHA primary prevention guideline^[3] lists an elevated Lp(a) of 50 mg/dL or higher (approximately 125 nmol/L) as a risk-enhancing factor — meaning it can inform the clinician-patient discussion about whether additional cardiovascular risk reduction interventions are appropriate. The AHA’s Lp(a) Toolkit for clinicians^[4] further describes Lp(a) as increasing relative risk of cardiovascular events by approximately 20% in individuals with levels above 50 mg/dL.

European Society of Cardiology / European Atherosclerosis Society (ESC/EAS): The most recent ESC/EAS focused update published in 2025^[1] made Lp(a) a recognized cardiovascular risk-enhancing factor with a Class IIa recommendation and Level B evidence, and expanded screening to include all adults at least once in their lifetime.

The important caveat: As noted by the ACC in a 2023 review^[5], while testing once in adulthood is increasingly discussed and supported by major guidelines, there is not yet a specific Lp(a)-lowering therapy proven in a large randomized cardiovascular outcomes trial. Several investigational agents are in advanced clinical development. The clinical value of Lp(a) measurement currently lies in refining overall cardiovascular risk assessment and prompting more intensive management of other modifiable risk factors — not in treating the Lp(a) level itself with a currently available drug.

Common Drivers and Causes (Population-Level)

Elevated Lp(a) is primarily genetically determined:

• Genetic variants in the LPA gene control Lp(a) production and are the dominant driver of high levels. An estimated 1 in 5 individuals worldwide has an Lp(a) level above 50 mg/dL, according to ESC/EAS 2025 guidance^[1].
• Ethnicity. Black individuals tend to have higher Lp(a) levels than white individuals on average, with some studies suggesting this contributes to disparate cardiovascular risk patterns.
• Hormonal changes. Post-menopausal women may see a rise in Lp(a) compared to pre-menopausal levels, which is one reason the ESC/EAS guidelines suggest^[1] a repeat test for women after menopause if pre-menopausal levels were borderline.
• Familial hypercholesterolemia (FH). People with inherited high cholesterol conditions are more likely to also have elevated Lp(a), compounding their cardiovascular risk.

Because Lp(a) is largely inherited, diet and most lifestyle changes have minimal effect on the level itself — though they remain very important for managing overall cardiovascular risk.

What Screening, Labs, or Follow-Up Evaluations May Be Considered

The following is general educational information; what applies to any individual depends on their complete clinical picture.

• Confirmation of Lp(a) level and units. Because labs may report results in mg/dL or nmol/L, and the ratio between units varies, confirming which units were used helps properly categorize risk.
• Complete lipid panel and cardiovascular risk assessment. Lp(a) is interpreted in the context of overall cardiovascular risk — including LDL, HDL, triglycerides, blood pressure, blood sugar, family history, and smoking status.
• Coronary artery calcium (CAC) scoring. For individuals where Lp(a) elevation adds uncertainty to cardiovascular risk categorization, CAC scoring (a non-invasive CT-based test assessing calcium in coronary arteries) may be discussed as a further risk stratification tool. Research cited in PMC cardiovascular risk reviews^[6] suggests that people with elevated Lp(a) and a CAC score above 100 face particularly elevated risk.
• Cascade screening of first-degree relatives. Because Lp(a) is heritable, the NLA supports offering testing to close relatives of individuals with elevated results.
• Intensified management of other risk factors. When Lp(a) is elevated, the current evidence-based approach emphasizes bringing all other modifiable cardiovascular risk factors — particularly LDL cholesterol — to optimal levels.

Lifestyle and Prevention Factors Evidence Supports

Because Lp(a) itself is largely unresponsive to diet and exercise, lifestyle work for this population focuses on lowering overall cardiovascular risk through other modifiable pathways:

• Lowering LDL cholesterol. The primary current strategy for managing elevated Lp(a) cardiovascular risk is addressing all other lipid abnormalities, particularly LDL. This is a discussion for clinician and patient.
• Blood pressure control. Elevated blood pressure combined with elevated Lp(a) compounds risk. Regular blood pressure monitoring and management are relevant.
• Not smoking. Smoking is a major independent cardiovascular risk factor and interacts with other risk factors to multiply risk.
• Blood sugar management. Maintaining normal blood glucose levels reduces overall cardiovascular risk.
• Heart-healthy dietary patterns. Mediterranean-style or DASH dietary patterns are associated with reduced cardiovascular risk through multiple pathways, even if they do not lower Lp(a) directly.
• Regular physical activity. Exercise lowers blood pressure, improves lipid profiles (HDL, triglycerides), and reduces cardiovascular risk overall.
• Maintaining a healthy weight. Obesity raises cardiovascular risk through multiple mechanisms.

Questions to Bring to Your Appointment

Questions you may want to discuss with your clinician include:

• What was my specific Lp(a) result, and which units — mg/dL or nmol/L — was it reported in?
• How does my Lp(a) level affect my overall cardiovascular risk picture when combined with my other risk factors?
• Should my Lp(a) result change anything about how aggressively we manage my LDL or blood pressure?
• Would a coronary artery calcium (CAC) score test help clarify my overall cardiovascular risk?
• Should my first-degree relatives — children, siblings, parents — consider getting their Lp(a) tested?
• Are there any investigational therapies or clinical trials related to Lp(a) lowering that I might be eligible for?
• Is there anything I should be doing differently in terms of diet, exercise, or monitoring given my Lp(a) level?
• How often should I have my overall cardiovascular risk reassessed now that we know my Lp(a)?
• Does my Lp(a) level affect any discussions about aspirin or other preventive therapies?
• Are there symptoms or changes that should prompt me to contact you sooner?
• What does “risk-enhancing factor” mean practically — does my result change what medications or tests we discuss?

Red Flags Warranting Prompter Follow-Up

Contact your clinician sooner if you experience:

• Chest pain, pressure, or tightness, especially during exertion
• Shortness of breath at rest or with minimal activity
• Sudden weakness, numbness, or difficulty speaking (possible stroke signs — call 911 immediately)
• Palpitations, irregular heartbeat, or unexplained near-fainting
• Pain in the jaw, left arm, or between the shoulder blades, especially with exertion
• Leg pain with walking that resolves with rest (possible peripheral artery disease)

Elevated Lp(a) alone does not cause acute symptoms — but combined with other risk factors, it increases the background risk for the cardiovascular events listed above.

Key Takeaways

• Lp(a) is a genetically determined lipid particle that is an independent, causal risk factor for heart attack, stroke, and aortic valve disease.
• An estimated 1 in 5 people has an Lp(a) level above the risk threshold of 50 mg/dL (125 nmol/L).
• The NLA, ESC/EAS, and ACC/AHA all now support Lp(a) measurement at least once in adulthood as part of cardiovascular risk assessment — though the strength and specific wording of recommendations varies by guideline body.
• Because Lp(a) is genetically determined and stable, a single test has lasting relevance and units (mg/dL vs. nmol/L) matter for interpretation.
• There is currently no approved medication specifically targeting Lp(a), but investigational therapies are in advanced trials; the current approach focuses on aggressively managing all other modifiable cardiovascular risk factors.
• First-degree relatives of individuals with elevated Lp(a) may benefit from cascade screening.

Disclaimer: This content is for general educational purposes only and is not medical advice. It does not create a doctor-patient relationship. Always talk to your licensed healthcare professional about your specific situation.

Post Views: 7

Disclosure: This site contains some affiliate links. We might receive a small commission at no additional cost to you.

Lipoprotein(a), written as Lp(a) and pronounced “L-P-little-a,” is a particle in the bloodstream that has emerged as one of the most important genetically determined cardiovascular risk factors. Unlike LDL cholesterol, which responds substantially to diet and medications, your Lp(a) level is largely set by your genes from early in life and changes little over time. An elevated result on a Lp(a) test does not mean a heart attack is imminent — but it does represent meaningful information worth a thorough conversation with your clinician. This article explains what Lp(a) is, what evolving guidelines say, and which questions to bring to your appointment.

What This Means in Plain Language

Lp(a) is a type of lipoprotein particle — similar in structure to LDL cholesterol — that contains an additional protein called apolipoprotein(a). This particle is thought to be pro-atherogenic (contributing to plaque buildup in arteries) and pro-thrombotic (contributing to clot formation). Research has consistently found that higher Lp(a) levels are associated with elevated risk for heart attack, stroke, and aortic valve calcification.

What makes Lp(a) unusual in cardiovascular risk assessment is how stable it is. According to updated ESC/EAS dyslipidemia guidelines highlighted by Roche Diagnostics^[1], Lp(a) levels are genetically determined, remain remarkably stable over a person’s lifetime, and are not significantly influenced by diet or exercise. This means a single test result has lasting relevance.

Levels are reported in either milligrams per deciliter (mg/dL) or nanomoles per liter (nmol/L), and the units matter because the relationship between them is not a simple fixed conversion. The National Lipid Association (NLA)^[2] classifies levels below 75 nmol/L (approximately 30 mg/dL) as low risk, 75–125 nmol/L (approximately 30–50 mg/dL) as intermediate risk, and 125 nmol/L or above (approximately 50 mg/dL or above) as high risk. When asking about your result, it helps to confirm which units were used.

Why Guidelines Pay Attention

The clinical consensus around Lp(a) has been evolving rapidly. Here is where major guideline bodies currently stand:

National Lipid Association (NLA): A 2024 focused NLA update^[2] recommended measurement of Lp(a) levels at least once in every adult for cardiovascular risk stratification. The NLA also supports cascade screening of first-degree relatives of patients with elevated Lp(a), because Lp(a) elevation runs in families.

American College of Cardiology / American Heart Association (ACC/AHA): The 2019 ACC/AHA primary prevention guideline^[3] lists an elevated Lp(a) of 50 mg/dL or higher (approximately 125 nmol/L) as a risk-enhancing factor — meaning it can inform the clinician-patient discussion about whether additional cardiovascular risk reduction interventions are appropriate. The AHA’s Lp(a) Toolkit for clinicians^[4] further describes Lp(a) as increasing relative risk of cardiovascular events by approximately 20% in individuals with levels above 50 mg/dL.

European Society of Cardiology / European Atherosclerosis Society (ESC/EAS): The most recent ESC/EAS focused update published in 2025^[1] made Lp(a) a recognized cardiovascular risk-enhancing factor with a Class IIa recommendation and Level B evidence, and expanded screening to include all adults at least once in their lifetime.

The important caveat: As noted by the ACC in a 2023 review^[5], while testing once in adulthood is increasingly discussed and supported by major guidelines, there is not yet a specific Lp(a)-lowering therapy proven in a large randomized cardiovascular outcomes trial. Several investigational agents are in advanced clinical development. The clinical value of Lp(a) measurement currently lies in refining overall cardiovascular risk assessment and prompting more intensive management of other modifiable risk factors — not in treating the Lp(a) level itself with a currently available drug.

Common Drivers and Causes (Population-Level)

Elevated Lp(a) is primarily genetically determined:

• Genetic variants in the LPA gene control Lp(a) production and are the dominant driver of high levels. An estimated 1 in 5 individuals worldwide has an Lp(a) level above 50 mg/dL, according to ESC/EAS 2025 guidance^[1].
• Ethnicity. Black individuals tend to have higher Lp(a) levels than white individuals on average, with some studies suggesting this contributes to disparate cardiovascular risk patterns.
• Hormonal changes. Post-menopausal women may see a rise in Lp(a) compared to pre-menopausal levels, which is one reason the ESC/EAS guidelines suggest^[1] a repeat test for women after menopause if pre-menopausal levels were borderline.
• Familial hypercholesterolemia (FH). People with inherited high cholesterol conditions are more likely to also have elevated Lp(a), compounding their cardiovascular risk.

Because Lp(a) is largely inherited, diet and most lifestyle changes have minimal effect on the level itself — though they remain very important for managing overall cardiovascular risk.

What Screening, Labs, or Follow-Up Evaluations May Be Considered

The following is general educational information; what applies to any individual depends on their complete clinical picture.

• Confirmation of Lp(a) level and units. Because labs may report results in mg/dL or nmol/L, and the ratio between units varies, confirming which units were used helps properly categorize risk.
• Complete lipid panel and cardiovascular risk assessment. Lp(a) is interpreted in the context of overall cardiovascular risk — including LDL, HDL, triglycerides, blood pressure, blood sugar, family history, and smoking status.
• Coronary artery calcium (CAC) scoring. For individuals where Lp(a) elevation adds uncertainty to cardiovascular risk categorization, CAC scoring (a non-invasive CT-based test assessing calcium in coronary arteries) may be discussed as a further risk stratification tool. Research cited in PMC cardiovascular risk reviews^[6] suggests that people with elevated Lp(a) and a CAC score above 100 face particularly elevated risk.
• Cascade screening of first-degree relatives. Because Lp(a) is heritable, the NLA supports offering testing to close relatives of individuals with elevated results.
• Intensified management of other risk factors. When Lp(a) is elevated, the current evidence-based approach emphasizes bringing all other modifiable cardiovascular risk factors — particularly LDL cholesterol — to optimal levels.

Lifestyle and Prevention Factors Evidence Supports

Because Lp(a) itself is largely unresponsive to diet and exercise, lifestyle work for this population focuses on lowering overall cardiovascular risk through other modifiable pathways:

• Lowering LDL cholesterol. The primary current strategy for managing elevated Lp(a) cardiovascular risk is addressing all other lipid abnormalities, particularly LDL. This is a discussion for clinician and patient.
• Blood pressure control. Elevated blood pressure combined with elevated Lp(a) compounds risk. Regular blood pressure monitoring and management are relevant.
• Not smoking. Smoking is a major independent cardiovascular risk factor and interacts with other risk factors to multiply risk.
• Blood sugar management. Maintaining normal blood glucose levels reduces overall cardiovascular risk.
• Heart-healthy dietary patterns. Mediterranean-style or DASH dietary patterns are associated with reduced cardiovascular risk through multiple pathways, even if they do not lower Lp(a) directly.
• Regular physical activity. Exercise lowers blood pressure, improves lipid profiles (HDL, triglycerides), and reduces cardiovascular risk overall.
• Maintaining a healthy weight. Obesity raises cardiovascular risk through multiple mechanisms.

Questions to Bring to Your Appointment

Questions you may want to discuss with your clinician include:

• What was my specific Lp(a) result, and which units — mg/dL or nmol/L — was it reported in?
• How does my Lp(a) level affect my overall cardiovascular risk picture when combined with my other risk factors?
• Should my Lp(a) result change anything about how aggressively we manage my LDL or blood pressure?
• Would a coronary artery calcium (CAC) score test help clarify my overall cardiovascular risk?
• Should my first-degree relatives — children, siblings, parents — consider getting their Lp(a) tested?
• Are there any investigational therapies or clinical trials related to Lp(a) lowering that I might be eligible for?
• Is there anything I should be doing differently in terms of diet, exercise, or monitoring given my Lp(a) level?
• How often should I have my overall cardiovascular risk reassessed now that we know my Lp(a)?
• Does my Lp(a) level affect any discussions about aspirin or other preventive therapies?
• Are there symptoms or changes that should prompt me to contact you sooner?
• What does “risk-enhancing factor” mean practically — does my result change what medications or tests we discuss?

Red Flags Warranting Prompter Follow-Up

Contact your clinician sooner if you experience:

• Chest pain, pressure, or tightness, especially during exertion
• Shortness of breath at rest or with minimal activity
• Sudden weakness, numbness, or difficulty speaking (possible stroke signs — call 911 immediately)
• Palpitations, irregular heartbeat, or unexplained near-fainting
• Pain in the jaw, left arm, or between the shoulder blades, especially with exertion
• Leg pain with walking that resolves with rest (possible peripheral artery disease)

Elevated Lp(a) alone does not cause acute symptoms — but combined with other risk factors, it increases the background risk for the cardiovascular events listed above.

Key Takeaways

• Lp(a) is a genetically determined lipid particle that is an independent, causal risk factor for heart attack, stroke, and aortic valve disease.
• An estimated 1 in 5 people has an Lp(a) level above the risk threshold of 50 mg/dL (125 nmol/L).
• The NLA, ESC/EAS, and ACC/AHA all now support Lp(a) measurement at least once in adulthood as part of cardiovascular risk assessment — though the strength and specific wording of recommendations varies by guideline body.
• Because Lp(a) is genetically determined and stable, a single test has lasting relevance and units (mg/dL vs. nmol/L) matter for interpretation.
• There is currently no approved medication specifically targeting Lp(a), but investigational therapies are in advanced trials; the current approach focuses on aggressively managing all other modifiable cardiovascular risk factors.
• First-degree relatives of individuals with elevated Lp(a) may benefit from cascade screening.

Disclaimer: This content is for general educational purposes only and is not medical advice. It does not create a doctor-patient relationship. Always talk to your licensed healthcare professional about your specific situation.

Post Views: 7